NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that today Novelos is presenting a scientific poster, based on the collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina (MUSC), at the ongoing American Association for Cancer Research (AACR) annual meeting in San Diego, CA. This presentation will describe findings in cellular and animal model systems that demonstrate the ability of NOV-002 to influence redox balance in and around cells, resulting in a constellation of effects on redox-sensitive cell processes and functions. An abstract of the poster presentation will also be published in the 2008 Proceedings of the AACR. NOV-002 is the subject of an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track, and is in Phase 2 trials for other oncology indications.
